Clinical Trials Browser

Immune Checkpoint Inhibitors × Gynecologic × Clear all

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Phase 2 Completed

84 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Phase 2 Recruiting

37 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

SYLVER

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer